The National Institute on Drug Abuse (NIDA), through the Drug Use and Addiction Research Programs (CFDA 93.279), has awarded a $1,420,405 Project Grant to Myosin Therapeutics Inc. to conduct a first-in-human Phase 1b clinical trial for their novel therapeutic agent MT-110. The purpose of this grant is to support a double-blind, placebo-controlled, single ascending dose study of MT-110 in individuals with methamphetamine use disorder (MUD). The study aims to determine the safety, tolerability, and pharmacokinetics of MT-110, as well as explore its potential effects on methamphetamine craving. This research is particularly relevant given the high prevalence of MUD, the limited treatment options, and the significant need for new pharmacotherapies to address the persistent risk of relapse. The award period runs from April 1, 2025, to March 31, 2027.
Generated 3/25/25, 5:04 AM